KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Taxes (2016 - 2019)

Biomarin Pharmaceutical (BMRN) has disclosed Current Taxes for 10 consecutive years, with $11.4 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Current Taxes rose 11.06% year-over-year to $11.4 million, compared with a TTM value of $11.4 million through Mar 2019, up 11.06%, and an annual FY2018 reading of $7.8 million, down 20.07% over the prior year.
  • Current Taxes was $11.4 million for Q1 2019 at Biomarin Pharmaceutical, up from $7.8 million in the prior quarter.
  • Across five years, Current Taxes topped out at $59.6 million in Q4 2015 and bottomed at $2.7 million in Q2 2018.
  • Average Current Taxes over 5 years is $11.6 million, with a median of $8.6 million recorded in 2017.
  • The sharpest move saw Current Taxes surged 987.28% in 2015, then plummeted 86.83% in 2016.
  • Year by year, Current Taxes stood at $59.6 million in 2015, then tumbled by 86.83% to $7.8 million in 2016, then grew by 24.11% to $9.7 million in 2017, then dropped by 20.07% to $7.8 million in 2018, then skyrocketed by 45.81% to $11.4 million in 2019.
  • Business Quant data shows Current Taxes for BMRN at $11.4 million in Q1 2019, $7.8 million in Q4 2018, and $2.7 million in Q2 2018.